Company: Mitokine Bioscience LLC
Top Gun: Dr. Brooke Ligon, founder and chief science officer
Employees: 1 full-time, 4 part-time
Mitokine Bioscience is an early-stage biopharmaceutical company currently
focussed on research and development of critical new treatments for
diabetes. Last November, Mitokine filed two patent applications for U.S. and foreign rights for additional intellectual property protection of the diabetes treatments the company discovered. Trials in mice and dogs are continuing to further establish efficacy and safety data.
Until Mitokine’s products receive FDA approval, the company depends on federal and state funding.